QGEN - FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation | Benzinga
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC), who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) results.
Bristol Myers Squibb added adagrasib via its $5 billion Mirati Therapeutics Inc. deal.
The approval is based on ...